The Temel et al. 2010 NEJM randomised trial of early palliative care integration in metastatic non-small-cell lung cancer produced three unexpected findings: patients in the early palliative care arm had better quality of life, received significantly less aggressive care in the final 60 days of life — and lived a median of 2.7 months longer than patients receiving standard oncology care alone (11.6 vs. 8.9 months). The survival advantage has been replicated in subsequent trials across cancer types and represents the strongest evidence that early palliative integration is not a compromise with longevity but a complement to it. The mechanism is understood: patients with better symptom control and psychological support tolerate treatment better, make more considered decisions about additional interventions, and spend less time in late-stage aggressive treatments that produce no benefit while accelerating decline.
The regret data follow from these outcome differences. Prigerson et al.’s 2009 JAMA Coping with Cancer study found that bereaved family members of advanced cancer patients who received chemotherapy in the final week of life had a 35% PTSD rate at 6-month follow-up, compared with 19% for families of patients who had enrolled in hospice. Family PTSD is the methodologically standard proxy for regret in end-of-life research because patients who received the care cannot self-report. The ENABLE III trial found approximately 10% of bereaved families in the palliative-integration arm expressed regret about the approach. The 35 vs. 10 percentage point gap reflects a structural asymmetry: aggressive end-of-life treatment tends to be experienced as “not enough time together” regardless of outcome, while integrated supportive care tends to be remembered as “they were comfortable and present in a way that mattered.”
The action-dominates pattern in this entry reflects a specific population: adults with advanced/metastatic cancer where curative treatment is no longer the goal. The finding has no bearing on early-stage curable cancers, where aggressive treatment is unambiguously appropriate. “Early palliative care” in the Temel/ENABLE tradition is not hospice-only or abandonment of cancer treatment — it is palliative support integrated from diagnosis alongside active oncology. The Dartmouth Atlas of Health Care documents wide geographic variation in end-of-life cancer care intensity across US hospitals with no corresponding survival benefit from higher intensity, suggesting the aggressive end-of-life treatment pattern is a systemic default rather than a personally optimised choice. The clinical evidence now consistently supports offering early palliative integration as a standard component of advanced cancer care, not as an alternative to it.